iOWH 032

Drug Profile

iOWH 032

Alternative Names: iOWH032

Latest Information Update: 21 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute for OneWorld Health
  • Developer Institute for OneWorld Health; PATH
  • Class Amides; Antidiarrhoeals; Bromobenzenes; Heterocyclic compounds; Oxadiazoles; Phenyl ethers; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diarrhoea

Most Recent Events

  • 04 Apr 2014 PATH & the Bill and Melinda Gates Foundation plan a phase II trial for Diarrhoea (due to cholera) in Bangladesh (NCT02111304)
  • 26 Nov 2013 The Institute for OneWorld Health & the Program for Appropriate Technology in Health complete a phase I/II trial in Diarrhoea (due to cholera) in Bangladesh (NCT01823939)
  • 21 May 2013 Phase-I/II clinical trials in Diarrhoea (due to cholera) in Bangladesh (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top